0.6962 0.001 (0.19%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.9 | 1-year : | 1.06 |
Resists | First : | 0.77 | Second : | 0.9 |
Pivot price | 0.68 | |||
Supports | First : | 0.67 | Second : | 0.61 |
MAs | MA(5) : | 0.7 | MA(20) : | 0.69 |
MA(100) : | 0.64 | MA(250) : | 0.79 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 53.9 | D(3) : | 55.7 |
RSI | RSI(14): 51.5 | |||
52-week | High : | 1.28 | Low : | 0.37 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FBRX ] has closed below upper band by 40.9%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.74 - 0.74 | 0.74 - 0.75 |
Low: | 0.66 - 0.67 | 0.67 - 0.67 |
Close: | 0.69 - 0.7 | 0.7 - 0.7 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Mon, 25 Mar 2024
What Makes Forte Biosciences (FBRX) a New Buy Stock - Yahoo Finance
Mon, 25 Mar 2024
Forte Biosciences, Inc. (NASDAQ:FBRX) Forecasted to Earn FY2024 Earnings of ($0.41) Per Share - Defense World
Thu, 21 Mar 2024
Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Thu, 14 Mar 2024
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Sat, 09 Dec 2023
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully - Yahoo Finance
Tue, 14 Nov 2023
Insider Traders Lose US$62k As Forte Biosciences Drops - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 36 (M) |
Shares Float | 22 (M) |
Held by Insiders | 10.8 (%) |
Held by Institutions | 56.1 (%) |
Shares Short | 67 (K) |
Shares Short P.Month | 49 (K) |
EPS | -1 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.97 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -50.2 % |
Return on Equity (ttm) | -85 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.9 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -29 (M) |
Levered Free Cash Flow | -17 (M) |
PE Ratio | -0.7 |
PEG Ratio | 0 |
Price to Book value | 0.71 |
Price to Sales | 0 |
Price to Cash Flow | -0.89 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |